Risikobewertung des COVID-19-Impfstoffs Comirnaty aufgrund von Angaben im Periodic Safety Update Report

This procedure is a written question regarding the risk assessment of the Comirnaty COVID-19 vaccine. It focuses on analyzing safety data contained within the Periodic Safety Update Report to ensure the vaccine's continued safety for the public. This primarily affects healthcare providers and citizens receiving the vaccine, as it seeks transparency on potential side effects and the regulatory oversight of vaccine safety.